Kister I, et al. - Researchers examined predictors of “post-disease modifying therapy” (DMT) relapses and confirmed disability progression (CDP) in a diverse group of patients exposed to different DMTs. Using Cox proportional hazards regression, predictors of time to first relapse and 3-month CDP were analyzed, adjusting for age, gender, baseline EDSS, EDSS stability and a relapse-free period for ≥1 year prior to discontinuation, calendar epoch, index DMT, and the reason for discontinuation. The annualized relapse rate was 0.224 and confirmed disability progression rate was 8.23 per 100 person-years during the post-discontinuation period. Younger patients, female patients, and those with moderate disability were some of the characteristics of patients with a higher risk of post-DMT relapse. Among the DMTs, only natalizumab was linked to increased risk of both post-DMT relapse and CDP. Information regarding post-DMT relapse and disability progression rates and predictors of post-DMT disease activity allows for a more informed discussion about DMT discontinuation with patients considering this alternative.